Similar Articles |
|
Pharmaceutical Executive May 1, 2012 |
Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity? |
Pharmaceutical Executive May 1, 2011 Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
Pharmaceutical Executive May 1, 2012 |
Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory. |
Pharmaceutical Executive September 1, 2014 William Looney |
Ireland's Celtic Tiger: Back on the Hunt Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products. |
Chemistry World March 20, 2008 Richard Van Noorden |
UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market. |
Pharmaceutical Executive December 1, 2010 Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive August 1, 2011 Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. |
Pharmaceutical Executive January 21, 2014 Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
Pharmaceutical Executive August 1, 2012 |
Country Report: Mexico Jim O'Neill, chief economist at Goldman Sachs declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. The Mexican pharmaceutical industry has seen some significant changes over the last four years. |
Pharmaceutical Executive September 1, 2013 William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive September 1, 2014 |
Country Report: Spain Spain's recession-battered pharma sector adapts to a changing market environment and repositions itself for a return to healthy growth through expanding opportunities abroad. |
Chemistry World January 3, 2013 Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
Pharmaceutical Executive August 1, 2014 Ben Comer |
Pharm Exec's 2014 Emerging Pharma Leaders This year's class of 15 young executives is deeply of the moment, with wide-ranging therapeutic, business, and operational expertise. |
Pharmaceutical Executive September 1, 2012 Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive August 1, 2008 Sarah Houlton |
Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared. |
Pharmaceutical Executive April 1, 2012 |
Country Report: Ukraine Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts. But what has such rapid development done for the country's healthcare? |
Pharmaceutical Executive February 1, 2007 Sarah Houlton |
Global Report: Under One Roof The UK government is planning to set up a single body to oversee all health research in universities and hospitals - and to facilitate partnerships between government agencies and industry. |
Pharmaceutical Executive October 1, 2012 |
Country Report: Turkey In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East. The pharmaceutical industry has also enjoyed a wave of expansion. |
Chemistry World December 22, 2011 Sarah Houlton |
Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition. |
Chemistry World August 23, 2012 Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Pharmaceutical Executive October 1, 2014 William Looney |
IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today. |
Pharmaceutical Executive August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
Pharmaceutical Executive July 1, 2009 |
The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets. |
Pharmaceutical Executive January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Pharmaceutical Executive February 1, 2013 |
Country Report: Australia In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally. |
Pharmaceutical Executive December 1, 2006 Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
Pharmaceutical Executive February 1, 2012 |
Brazil Report: A Bold Player Blooms Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now. |
Pharmaceutical Executive January 1, 2012 William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Bio-IT World October 14, 2004 Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
Chemistry World December 8, 2011 Maria Burke |
Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry. |
Pharmaceutical Executive January 21, 2014 William Looney |
Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector |
Chemistry World March 7, 2008 Peter Mitchell |
Uk Drug Pricing System Scrapped The UK government is scrapping its existing national scheme for controlling drug prices. The system, called the Pharmaceutical price regulation scheme (PPRS), will be replaced by a newly negotiated agreement on 1 September 2008. |
Chemistry World June 18, 2008 Ananyo Bhattacharya |
Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service |
Pharmaceutical Executive October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
Chemistry World December 17, 2015 Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
Pharmaceutical Executive June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Pharmaceutical Executive January 1, 2013 William Looney |
The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace. |
Pharmaceutical Executive October 1, 2011 |
Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy. |
Pharmaceutical Executive December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
Pharmaceutical Executive October 1, 2008 Sarah Houlton |
Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems. |
Pharmaceutical Executive July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
Pharmaceutical Executive June 1, 2013 Julian Upton |
Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property. |
Pharmaceutical Executive July 1, 2012 William Looney |
The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good. |
Pharmaceutical Executive October 1, 2006 Ray Hill |
China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge. |
Pharmaceutical Executive September 1, 2006 Jill Wechsler |
Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world. |
Pharmaceutical Executive April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Pharmaceutical Executive October 1, 2014 Leela Barham |
The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine. |
Pharmaceutical Executive July 1, 2013 Looney et al. |
Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what? |